Published in Cancer Res on August 15, 1991
Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver. Am J Pathol (1999) 1.09
Hepatitis B virus infection and primary hepatocellular carcinoma. Clin Microbiol Rev (1992) 1.04
Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks. World J Gastroenterol (1999) 1.01
Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations. Br J Cancer (1999) 0.97
Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer (2001) 0.96
Evidence for the presence of two tumour-suppressor genes for hepatocellular carcinoma on chromosome 13q. Br J Cancer (1995) 0.92
Loss of heterozygosity of the retinoblastoma gene in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol (1997) 0.81
Investigation of chromosomal aberrations in Egyptian hepatocellular carcinoma patients by fluorescence in situ hybridization. Indian J Hum Genet (2010) 0.75
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology (1990) 6.53
Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet (2000) 4.74
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet (1999) 2.15
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer (2005) 2.13
Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J Cell Sci (1996) 1.99
A Taq I polymorphism for the human transforming growth factor alpha gene (TGFA). Nucleic Acids Res (1987) 1.88
Genome scan of schizophrenia. Am J Psychiatry (1998) 1.74
Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res (2000) 1.72
MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet (2001) 1.67
A novel variant genotype C of hepatitis B virus identified in isolates from Australian Aborigines: complete genome sequence and phylogenetic relatedness. J Gen Virol (2001) 1.67
Leptin and the risk of Barrett's oesophagus. Gut (2008) 1.54
Improved growth and clinical, nutritional, and respiratory changes in response to nutritional therapy in cystic fibrosis. J Pediatr (1980) 1.52
Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers. J Clin Invest (1983) 1.52
The CDKN2A (p16) gene and human cancer. Mol Med (1997) 1.46
Comparison of four methods for quantitative measurement of hepatitis B viral DNA. J Hepatol (1996) 1.45
Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. Eur Respir J (2007) 1.43
Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol (1996) 1.36
Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res (1997) 1.33
Enhanced drug metabolism in cigarette smokers. Br Med J (1976) 1.31
The contribution of the DFNB1 locus to neurosensory deafness in a Caucasian population. Am J Hum Genet (1995) 1.30
Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer (1996) 1.25
Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res (1994) 1.24
Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet (1995) 1.18
Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther (1979) 1.13
Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res (1995) 1.10
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res (1996) 1.10
CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res (1997) 1.07
Wilson's disease in an Australian aborigine. J Gastroenterol Hepatol (1991) 1.07
Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust (2000) 1.05
The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology (1986) 1.04
UK guidance for non-heart-beating donation. Br J Anaesth (2005) 1.04
Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia. Mol Psychiatry (2005) 1.04
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst (2010) 1.04
Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res (2001) 1.03
Monosomy of a "G" autosome in a 22-year-old female. Med J Aust (1973) 1.02
Australia antigen in active chronic hepatitis in Australia: results in 130 patients from three centres. Aust N Z J Med (1972) 1.01
Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism. Gastroenterology (1978) 1.01
Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int J Cancer (1991) 1.00
Second stage of a genome scan of schizophrenia: study of five positive regions in an expanded sample. Am J Med Genet (2000) 0.98
Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Inst (1997) 0.98
A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol (2000) 0.97
Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis. Am J Hum Genet (2000) 0.97
The incidence of oxyphenisatin ingestion in active chronic hepatitis: a prospective controlled study of 29 patients. Aust N Z J Med (1973) 0.97
Functional reassessment of P16 variants using a transfection-based assay. Int J Cancer (1999) 0.97
Cell-mediated immunity to liver antigen in toxic liver injury. I. Occurrence and specificity. Clin Exp Immunol (1980) 0.95
The nature of piecemeal necrosis in chronic active hepatitis. Lancet (1979) 0.95
Reticuloendothelial phagocytic function in human liver disease and its relationship to haemolysis. Br J Haematol (1973) 0.95
Hepatocellular carcinoma mutation. Nature (1991) 0.95
Involvement of the skin and subcutaneous tissue in azotaemic hyperparathyroidism. Aust N Z J Med (1972) 0.94
Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene (1997) 0.94
Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med (1994) 0.93
A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer (1995) 0.93
A longitudinal analysis of cytotoxic T lymphocyte precursor frequencies to the hepatitis B virus in chronically infected patients. J Viral Hepat (2001) 0.93
Improvement in chronic hepatocerebral degeneration following liver transplantation. Gastroenterology (1990) 0.92
Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clin Pharmacol Ther (1990) 0.92
Cell-mediated immunity to liver antigen in toxic liver injury. II. Role in pathogenesis of liver damage. Clin Exp Immunol (1980) 0.91
Exposure to GB virus type C or hepatitis G virus in selected Australian adult and children populations. Transfusion (1998) 0.90
Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees. Genomics (1992) 0.90
Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat (1998) 0.90
HBsAg-induced antigen-specific T and B lymphocyte responses in chronic hepatitis B virus carriers and immune individuals. Clin Exp Immunol (1989) 0.90
Histological patterns of prolonged hepatitis C infection. Gastroenterol Jpn (1993) 0.90
Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene (1995) 0.89
Changes in body composition and muscle protein degradation during nutritional supplementation in nutritionally growth-retarded children with cystic fibrosis. J Pediatr Gastroenterol Nutr (1983) 0.89
Mononuclear cell factors that inhibit fibroblast collagen synthesis. I. In vitro conditions determining their production and expression. Scand J Immunol (1983) 0.88
Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res (2002) 0.88
The phospholipase C beta 3 gene located in the MEN1 region shows loss of expression in endocrine tumours. Hum Mol Genet (1994) 0.88
PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res (2002) 0.87
Altered body composition and muscle protein degradation in nutritionally growth-retarded children with cystic fibrosis. Am J Clin Nutr (1982) 0.87
p53 gene in hepatocellular carcinomas from Australia. Cancer Detect Prev (1994) 0.86
The regulatory roles of liver and kidney in cobalamin (vitamin B12) metabolism in the rat: the uptake and intracellular binding of cobalamin and the activity of the cobalamin-dependent enzymes in response to varying cobalamin supply. Clin Sci (Lond) (1984) 0.86
CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin. Int J Cancer (2001) 0.86
Multiple splicing variants of cdc25B regulate G2/M progression. Biochem Biophys Res Commun (1999) 0.86
Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma. Int J Cancer (1994) 0.86
Clonal loss of INT-2 alleles in sporadic and familial pancreatic endocrine tumours. Br J Cancer (1990) 0.86
Erythromycin jaundice: diagnosis by an in vitro challenge test. Aust N Z J Med (1977) 0.86
CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer (1997) 0.85
Evidence for microsatellite instability in bilateral breast carcinomas. Cancer Lett (2000) 0.85
Alterations in the liver with ageing. Clin Gastroenterol (1985) 0.85
The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol (1998) 0.85
Linkage mapping of melanoma (MLM) using 172 microsatellite markers. Genomics (1992) 0.85
Influence of alcohol and caffeine consumption on caffeine elimination. Clin Exp Pharmacol Physiol (1986) 0.85
Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice. Oncogene (2006) 0.83
Single base mutation in the hormone binding domain of the thyroid hormone receptor beta gene in generalised thyroid hormone resistance demonstrated by single stranded conformation polymorphism analysis. Biochem Biophys Res Commun (1991) 0.83
Involvement of p16CDKN2A in cell cycle delays after low dose UV irradiation. Mutat Res (1998) 0.83
Molecular tools for presymptomatic testing in multiple endocrine neoplasia type 1. J Intern Med (1995) 0.82
Origin of rare Ha-ras alleles: relationship of VTR length to a 5' polymorphic Xho I site. Genet Res (1989) 0.81
Loss of alleles on the short arm of chromosome 11 in a hepatoblastoma from a child with Beckwith-Wiedemann syndrome. Hum Genet (1988) 0.81
Whole body protein turnover in malnourished cystic fibrosis patients and its relationship to pulmonary disease. Am J Clin Nutr (1985) 0.81
Establishment of a cell line from a hepatocellular carcinoma from a patient with hemochromatosis. Hepatology (1994) 0.81
Loss of heterozygosity studies in squamous cell carcinomas of the head and neck. Head Neck (1997) 0.80
Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal. J Invest Dermatol (1997) 0.80
Hepatitis B transmission within families: potential importance of saliva as a vehicle of spread. Aust N Z J Med (1985) 0.80
Immunological abnormalities associated with liver disease: cause or effect? Aust N Z J Med (1977) 0.80
Are the causes and presentation of chronic hepatitis changing? An analysis of 104 cases over 15 years. Q J Med (1984) 0.80
Apoptosis as the mode of cell death in antibody-dependent lymphocytotoxicity. J Cell Sci (1985) 0.79
Ocular melanoma is not associated with CDKN2A or MC1R variants--a population-based study. Melanoma Res (2003) 0.79
Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer (1994) 0.79